102 related articles for article (PubMed ID: 21606156)
21. Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitor.
Green LJ; Marder P; Ray C; Cook CA; Jaken S; Musib LC; Herbst RS; Carducci M; Britten CD; Basche M; Eckhardt SG; Thornton D
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3408-15. PubMed ID: 16740765
[TBL] [Abstract][Full Text] [Related]
22. Enzastaurin inhibits ABCB1-mediated drug efflux independently of effects on protein kinase C signalling and the cellular p53 status.
Michaelis M; Rothweiler F; Löschmann N; Sharifi M; Ghafourian T; Cinatl J
Oncotarget; 2015 Jul; 6(19):17605-20. PubMed ID: 25749379
[TBL] [Abstract][Full Text] [Related]
23. Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia.
Moreau AS; Jia X; Ngo HT; Leleu X; O'Sullivan G; Alsayed Y; Leontovich A; Podar K; Kutok J; Daley J; Lazo-Kallanian S; Hatjiharissi E; Raab MS; Xu L; Treon SP; Hideshima T; Anderson KC; Ghobrial IM
Blood; 2007 Jun; 109(11):4964-72. PubMed ID: 17284528
[TBL] [Abstract][Full Text] [Related]
24. Protein kinase C-beta inhibitor enzastaurin (LY317615.HCI) enhances radiation control of murine breast cancer in an orthotopic model of bone metastasis.
Dudek AZ; Zwolak P; Jasinski P; Terai K; Gallus NJ; Ericson ME; Farassati F
Invest New Drugs; 2008 Feb; 26(1):13-24. PubMed ID: 17805485
[TBL] [Abstract][Full Text] [Related]
25. Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids.
Zatelli MC; Minoia M; Martini C; Tagliati F; Ambrosio MR; Schiavon M; Buratto M; Calabrese F; Gentilin E; Cavallesco G; Berdondini L; Rea F; degli Uberti EC
Endocr Relat Cancer; 2010 Sep; 17(3):719-29. PubMed ID: 20554786
[TBL] [Abstract][Full Text] [Related]
26. Anticancer Effects of Baicalein in Pancreatic Neuroendocrine Tumors In Vitro and In Vivo.
Tian Y; Zhen L; Bai J; Mei Y; Li Z; Lin A; Li X
Pancreas; 2017 Sep; 46(8):1076-1081. PubMed ID: 28787336
[TBL] [Abstract][Full Text] [Related]
27. Protein kinase C-beta gene variants, pathway activation, and enzastaurin activity in lung cancer.
Lee SH; Chen T; Zhou J; Hofmann J; Bepler G
Clin Lung Cancer; 2010 May; 11(3):169-75. PubMed ID: 20439192
[TBL] [Abstract][Full Text] [Related]
28. Enzastaurin-induced apoptosis in glioma cells is caspase-dependent and inhibited by BCL-XL.
Rieger J; Lemke D; Maurer G; Weiler M; Frank B; Tabatabai G; Weller M; Wick W
J Neurochem; 2008 Sep; 106(6):2436-48. PubMed ID: 18662322
[TBL] [Abstract][Full Text] [Related]
29. Correlations of mRNA expression and in vitro chemosensitivity to enzastaurin in freshly explanted human tumor cells.
Hanauske AR; Eismann U; Oberschmidt O; Pospisil H; Hanauske-Abel HM; Blatter J; Ma D; Chen V; Lahn M
Invest New Drugs; 2008 Jun; 26(3):215-22. PubMed ID: 18000644
[TBL] [Abstract][Full Text] [Related]
30. Insulin-like growth factor-1 increases intracellular calcium concentration in human primary neuroendocrine pancreatic tumor cells and a pancreatic neuroendocrine tumor cell line (BON-1) via R-type Ca2+ channels and regulates chromogranin a secretion in BON-1 cells.
Mergler S; Strauss O; Strowski M; Prada J; Drost A; Langrehr J; Neuhaus P; Wiedenmann B; Ploeckinger U
Neuroendocrinology; 2005; 82(2):87-102. PubMed ID: 16424676
[TBL] [Abstract][Full Text] [Related]
31. Generation and characterization of CRISPR/Cas9-mediated MEN1 knockout BON1 cells: a human pancreatic neuroendocrine cell line.
Monazzam A; Li SC; Wargelius H; Razmara M; Bajic D; Mi J; Bergquist J; Crona J; Skogseid B
Sci Rep; 2020 Sep; 10(1):14572. PubMed ID: 32884006
[TBL] [Abstract][Full Text] [Related]
32. Molecular targeting of the PKC-beta inhibitor enzastaurin (LY317615) in multiple myeloma involves a coordinated downregulation of MYC and IRF4 expression.
Verdelli D; Nobili L; Todoerti K; Intini D; Cosenza M; Civallero M; Bertacchini J; Deliliers GL; Sacchi S; Lombardi L; Neri A
Hematol Oncol; 2009 Mar; 27(1):23-30. PubMed ID: 18759374
[TBL] [Abstract][Full Text] [Related]
33. Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures.
Mohamed A; Blanchard MP; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Monges G; Garcia S; Ferone D; Florio T; Enjalbert A; Moutardier V; Schonbrunn A; Gerard C; Barlier A; Saveanu A
Endocr Relat Cancer; 2014 Oct; 21(5):691-704. PubMed ID: 25012983
[TBL] [Abstract][Full Text] [Related]
34. Atypical isoforms of pKc and insulin secretion from pancreatic beta-cells: evidence using Gö 6976 and Ro 31-8220 as Pkc inhibitors.
Harris TE; Persaud SJ; Jones PM
Biochem Biophys Res Commun; 1996 Oct; 227(3):672-6. PubMed ID: 8885992
[TBL] [Abstract][Full Text] [Related]
35. Type 2 Diabetes in Neuroendocrine Tumors: Are Biguanides and Statins Part of the Solution?
Herrera-Martínez AD; Pedraza-Arevalo S; L-López F; Gahete MD; Gálvez-Moreno MA; Castaño JP; Luque RM
J Clin Endocrinol Metab; 2019 Jan; 104(1):57-73. PubMed ID: 30265346
[TBL] [Abstract][Full Text] [Related]
36. mTOR inhibitors response and mTOR pathway in pancreatic neuroendocrine tumors.
Falletta S; Partelli S; Rubini C; Nann D; Doria A; Marinoni I; Polenta V; Di Pasquale C; Degli Uberti E; Perren A; Falconi M; Zatelli MC
Endocr Relat Cancer; 2016 Nov; 23(11):883-891. PubMed ID: 27697900
[TBL] [Abstract][Full Text] [Related]
37. Thermo-sensitive transient receptor potential vanilloid channel-1 regulates intracellular calcium and triggers chromogranin A secretion in pancreatic neuroendocrine BON-1 tumor cells.
Mergler S; Skrzypski M; Sassek M; Pietrzak P; Pucci C; Wiedenmann B; Strowski MZ
Cell Signal; 2012 Jan; 24(1):233-46. PubMed ID: 21945155
[TBL] [Abstract][Full Text] [Related]
38. Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
François RA; Maeng K; Nawab A; Kaye FJ; Hochwald SN; Zajac-Kaye M
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971297
[TBL] [Abstract][Full Text] [Related]
39. The anti-tumoral drug enzastaurin inhibits natural killer cell cytotoxicity via activation of glycogen synthase kinase-3β.
Ogbomo H; Biru T; Michaelis M; Loeschmann N; Doerr HW; Cinatl J
Biochem Pharmacol; 2011 Jan; 81(2):251-8. PubMed ID: 20934407
[TBL] [Abstract][Full Text] [Related]
40. Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?
Mohamed A; Romano D; Saveanu A; Roche C; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Garcia S; Ferone D; Florio T; Moutardier V; Poizat F; Barlier A; Gerard C
Oncotarget; 2017 Jun; 8(25):41044-41063. PubMed ID: 28454119
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
